US2020140460A1PendingUtilityA1
Antibacterial therapeutics and prophylactics
Est. expiryJul 28, 2035(~9 yrs left)· nominal 20-yr term from priority
Inventors:Shiladitya SenguptaShamik GhoshSumana GhoshMau SinhaSuresh SadhasivamAnamika BhattacharyyaSiva Ganesh MavuduruNupar TandonDeepak Kumar
A01N 43/46C07D 405/12C07D 513/04C07D 405/14A61P 31/04A61K 9/0019C07D 413/12C07D 263/48C07C 323/59A61K 9/0053C07D 263/38C07D 263/24C07D 403/12A01N 43/78C07D 239/96A01N 43/90C07D 401/12C07D 215/56A61P 13/02A01N 43/76A61K 47/36C07D 417/12A61K 47/34C07D 413/14A61K 47/10A61K 31/4743C07D 311/22A61P 17/10C07D 471/00C07C 323/60A61K 9/06A61K 47/12A61K 47/38C07D 487/04A61K 9/0014
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.
Claims
exact text as granted — not AI-modified1 . A compound of Formula (II):
wherein:
X is O, S, or N;
R 1 is H, C 1 -C 6 alkyl, —COCHY 2 , —COCH 2 Y, haloalkyl, CH 2 CN, amino, OCH 3 , COOCH 3 , SO 2 CH 3 , COCH 2 OH, or —[NHC(R 7 )] n -M;
R 2 and R 3 are independently H or halo;
R 4 is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R 4 is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R 4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R 4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or
R 4 is
where p is 0-10; M is CH, NH, or S; Y is NH, CH, O or S; L is a linker or Z; and Z is NH 2 , OH, SH, alkyl, —COOH, or CONH 2 ; or R 4 is a carbohydrate.
2 - 19 . (canceled)
20 . The compound of claim 1 selected from the group consisting of:
21 . The compound of claim 1 selected from the group consisting of:
22 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
23 . A composition for topical application comprising the compound of claim 1 .
24 . A composition for oral administration comprising the compound of claim 1 .
25 . A composition for administration by injection comprising the compound of claim 1 .
26 . A composition comprising a polymer matrix and the compound of claim 1 .
27 . A method for treating an infection, the method comprising administering a therapeutically effective amount of the compound of claim 1 to a subject in need thereof.
28 . The method of claim 27 , wherein said infection is caused by a resistant pathogen.
29 . The method of claim 27 , wherein said infection is caused by a methicillin-resistant or vancomycin-resistant pathogen.
30 . The method of claim 27 , wherein said infection is caused by a quinolone-resistant pathogen.
31 . A method for wound treatment, the method comprising applying the compound of claim 1 to a wound.
32 . A method for preventing or reducing infection caused by an implant, the method comprising applying the compound of claim 1 to the implant.
33 . A method for preventing or reducing infection caused by an implant, the method comprising administering the compound of claim 1 to a subject in need thereof.
34 . A method for the treatment of pneumonia, the method comprising administering the compound of claim 1 to a subject in need thereof.
35 . A method for the treatment of urinary tract infection, the method comprising administering the compound of claim 1 to a subject in need thereof.
36 . A method for the treatment of impetigo, the method comprising administering the compound of claim 1 to a subject in need thereof.
37 . A method for the treatment of acne, the method comprising administering the compound of claim 1 to a subject in need thereof.
38 . A method of inhibiting or reducing biofilm formation, the method comprising applying the compound of claim 1 to a surface or biofilm.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.